|1.||Raufman, Jean-Pierre: 5 articles (04/2009 - 10/2002)|
|2.||Cheng, Kunrong: 5 articles (04/2009 - 10/2002)|
|3.||Wess, Jürgen: 3 articles (01/2015 - 04/2014)|
|4.||Hylkema, Machteld N: 2 articles (01/2015 - 04/2014)|
|5.||Horsnell, William G C: 2 articles (01/2015 - 01/2007)|
|6.||Brombacher, Frank: 2 articles (01/2015 - 01/2007)|
|7.||Meurs, Herman: 2 articles (01/2015 - 04/2014)|
|8.||Kistemaker, Loes E M: 2 articles (01/2015 - 04/2014)|
|9.||Hiemstra, Pieter S: 2 articles (01/2015 - 04/2014)|
|10.||Kerstjens, Huib A M: 2 articles (01/2015 - 04/2014)|
|1.||Chronic Obstructive Pulmonary Disease (COPD)
11/14/2013 - "Antagonizing the human M3 muscarinic receptor (hM3R) over a long time is a key feature of modern bronchodilating COPD drugs aiming at symptom relief. "
04/01/2008 - "Bedtime inhalation of a novel muscarinic M3 receptor antagonist markedly lowered ambulatory blood pressure (ABP), predominantly during sleep, in a chronic obstructive pulmonary disease (COPD) patient with masked nocturnal hypertension. "
04/01/2008 - "Sleep-predominant lowering of ambulatory blood pressure by bedtime inhalation of a novel muscarinic M3 receptor antagonist: a new "bronchoantihypertensive" strategy targeting the lung in hypertension with chronic obstructive pulmonary disease."
12/01/2006 - "Because beta-agonists were expected to exacerbate the CHF, inhalation of tiotropium, a non-beta-adrenergic bronchodilator and novel M3 muscarinic receptor antagonist, was used to treat the COPD. "
12/01/2006 - "Tiotropium, a novel muscarinic M3 receptor antagonist, improved symptoms of chronic obstructive pulmonary disease complicated by chronic heart failure."
11/01/2007 - "Muscarinic M3 receptors exist in the gastrointestinal wall in humans and the muscarinic M3 agonist cevimeline hydrochloride (Evoxac) is a candidate therapeutic agent for the treatment of xerostomia in Sjögren's syndrome. "
04/01/2008 - "Cevimeline hydrochloride, a specific agonist of the M3 muscarinic receptor, is beneficial in the treatment of symptoms of xerostomia and xerophthalmia associated with Sjögren's syndrome (SS). "
01/01/1999 - "In this study we have investigated the agonist-triggered trafficking of the M3 muscarinic receptor expressed in SH-SY5Y human neuroblastoma cells. "
10/01/1994 - "Cell types examined include rat cerebellar granule cells, Chinese hamster ovary cells transfected to express the human muscarinic M3 receptor (CHO-M3 cells), and SH-SY5Y neuroblastoma cells. "
07/01/1992 - "LAN-1: a human neuroblastoma cell line with M1 and M3 muscarinic receptor subtypes coupled to intracellular Ca2+ elevation and lacking Ca2+ channels activated by membrane depolarization."
01/01/1992 - "M3 muscarinic receptors expressed on SH-SY5Y human neuroblastoma cells are linked to phosphoinositide turnover and rises in [Ca2+]i. The rise in [Ca2+]i is biphasic with the peak phase being due to release from an intracellular Ins(1,4,5)P3-sensitive site and the plateau phase being due to Ca2+ entry across the plasma membrane. "
08/01/1990 - "Depolarization by elevated K+ and stimulation of muscarinic M3 receptors evoke rises in [Ca2+]i in Fura 2-loaded SH-SY5Y human neuroblastoma cells. "
|4.||G-Protein-Coupled Receptors (Receptors, G Protein Coupled)
|6.||Growth Factor Receptors
|8.||Epidermal Growth Factor Receptor (EGF Receptor)
|9.||Epidermal Growth Factor (EGF)
|10.||Bile Acids and Salts (Bile Acids)
|1.||Heterologous Transplantation (Xenotransplantation)